WATERTOWN: EyePoint Pharmaceuticals, Inc. announced Monday it has commenced an underwritten public offering of $150 million of its common stock. The biopharmaceutical company, which focuses on treatments for serious retinal diseases, stated that all shares in the offering are being sold by the company. EyePoint also plans to grant the underwriters a 30-day option…